Market Challenges And Opportunities

Key Developments

Major market players are focused on gaining product approvals to expand their product portfolio. For instance, in August 2019, the U.S. FDA approved a US Medical Innovations LLC-developed cold atmospheric plasma system ‘Canady Helios Cold Plasma System and Scalpel’ for human clinical trials.

Major institutes are also focused on research and development activities related to cold plasma bio-welding technology. For instance, in September 2019, researchers from University of Antwerp, Belgium, evaluated the influence of the cell type, cancer type, and cell culture medium on direct and indirect cold atmospheric plasma treatment.

Similarly in August 2019, researchers from Leibniz Institute for Plasma Science and Technology found that plasma treatment is a safe and promising therapeutic option and that it does not promote metastatic behavior in pancreatic cancer cells in vitro and in ovo.